Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.48 |
| ▸ | MMP10 | P09238 | 3/20 | 0.45 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253135 | 0.94 | MMP13 (0.53) | MMP13MMP10MMP8MMP9PHGDH | |
| SCHEMBL10162335 | 0.94 | CACNA1G (0.43) | MMP13MMP10MMP8MMP9PDE2A | |
| SCHEMBL10165591 | 0.93 | MMP13 (0.51) | MMP13MMP10MMP8MMP9PDE2A | |
| SCHEMBL8256059 | 0.92 | MMP13 (0.47) | MMP13MMP10MMP8MMP9PDE2A | |
| SCHEMBL10162330 | 0.91 | MMP13 (0.39) | MMP13MMP10MMP8MMP9PDE2A | |
| SCHEMBL10162443 | 0.90 | MMP13 (0.55) | MMP13MMP10MMP8MMP9PDE2A | |
| SCHEMBL10165518 | 0.85 | MMP13 (0.60) | MMP13MMP10MMP8MMP9CACNA1G | |
| SCHEMBL10165795 | 0.85 | MMP13 (0.63) | MMP13MMP10MMP8MMP9CACNA1G | |
| SCHEMBL8256806 | 0.84 | MMP13 (0.53) | MMP13MMP10MMP8MMP9CACNA1G | |
| SCHEMBL10165542 | 0.83 | MMP13 (0.57) | MMP13MMP10MMP8MMP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885MMP10 4/4885MMP8 26/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | MMP13 1/4885MMP10 4/4885MMP8 26/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885MMP10 4/4885MMP8 26/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885MMP10 4/4885MMP8 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.